{"name":"Z Factor Limited","slug":"z-factor-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1RWURRenl6eE9SRjRnZWFZaWg2ZGg5U2FmeHNwR2FwazByODY1SmxjUmV6b0V0MFdna1BENXdQNk8yOFNLUm55cERUOEpaa3ZfUWl5TGxja0NGS2Y4YnRJ?oc=5","date":"2025-10-09","type":"regulatory","source":"Nature","summary":"Systematic over-expression of secondary metabolism transcription factors to reveal the pharmaceutical potential of Aspergillus nidulans - Nature","headline":"Systematic over-expression of secondary metabolism transcription factors to reveal the pharmaceutical potential of Asper","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5wRkRKZ1FoOEpCRWlTeFF3NllUdkxsTXF2bDgtSWlLeldNU0lTaTVzdEJKN21GWTNRRkM3ZGtfNVpZdnNVYlFLeWoyYmtQWjVfbGxqQVZzU3p1QWZ6UWRV?oc=5","date":"2025-05-08","type":"trial","source":"Nature","summary":"Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial - Nature","headline":"Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 tria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE16NlkzMFRHNGFiakNoTGJxUlZuaThkeDl6NFJiQzFNX3haVFlESzJTTlVCMnZLWDMtLV91aHVBdVZkOUg2dTgxOGxfVmdvVzdrUC1laXROZzVwWGlE?oc=5","date":"2025-04-29","type":"pipeline","source":"PNAS","summary":"NEUROD1 efficiently converts peripheral blood cells into neurons with partial reprogramming by pluripotency factors - PNAS","headline":"NEUROD1 efficiently converts peripheral blood cells into neurons with partial reprogramming by pluripotency factors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPeGxrTjFMQkhROXVKNFp1eHhDQ2tjeFNVS0VoUlB2Qm5tbnA1WDdnOGh3Qy00a2FhU2tFZGY5YmpibDljaDdHcFZzcWJ4M2haelFfZzJWOWN6SGFFT1hZaVlhWUZTRXd6VEx3czJfdWhSdzBFSk5QNi0wYXQwcFI4UHk1amgtejFETUVGa0VtMmptcHRLSTU2dmlzU2lrOGUwWEZ2V3B4SQ?oc=5","date":"2024-07-15","type":"pipeline","source":"The Association of the British Pharmaceutical Industry | ABPI","summary":"New research shows why Gen-Z is choosing to work in pharma - The Association of the British Pharmaceutical Industry | ABPI","headline":"New research shows why Gen-Z is choosing to work in pharma - The Association of the British Pharmaceutical Industry | AB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5LNllQQnZZOUdybUVFOUJvY1h1ZGduV252N3h3ZmF1SFZxZDlFWlMteG5oM05WQmkxbVg2elRPdDA2bm5aXzNYNHU0dW1uVHlJMkxrZWRBLXlWUFdXQW9z?oc=5","date":"2023-12-15","type":"pipeline","source":"Nature","summary":"Digitalization enhancement in the pharmaceutical supply network using a supply chain risk management approach - Nature","headline":"Digitalization enhancement in the pharmaceutical supply network using a supply chain risk management approach","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1uSWc5WEV3RnlOcGFhTi1WSnhFWUJpZzZPUEw4akxFM3V3dzdlT214UF9zQjh2SzdHNExPX3pZbWg0NVJOdW40aFI1Y1VXY1JCTjRyWEFhelc1WjFtZWJZ?oc=5","date":"2023-09-06","type":"trial","source":"Nature","summary":"Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials - Nature","headline":"Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOcnBxRy1aTGtQcWFwOS16X21KNkFxY2gwYm5HS2JVS2xRS3hkS24wUVZQQnBDLXJ4ZmNkM1AyNjBFdnVGZ1NzMC1fbXlUS1VBdldXWkNZOU1BMG55MjFVZ1BmMzh2ekRORnh6TjJfRGR6bHV5T3FGWmdVUmNraDB5REtUMWZVN2U4WE5FTg?oc=5","date":"2023-02-03","type":"pipeline","source":"Market.us","summary":"Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size - Market.us","headline":"Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4yY2dBbGl3bkw5ZEh1SzQ5S2N2Zm9Wc0EtOTg0bGtFRVNBSUNEbWdfZzVmdm5udll5U0ZMaElnOHVqZ3ZBcXdTa3dvTVpOeGRXLWJ6NWl5VmtPcHBtZUxr?oc=5","date":"2022-03-31","type":"trial","source":"Nature","summary":"Excess mortality in Belarus during the COVID-19 pandemic as the case study of a country with limited non-pharmaceutical interventions and limited reporting | Scientific Reports - Nature","headline":"Excess mortality in Belarus during the COVID-19 pandemic as the case study of a country with limited non-pharmaceutical ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQX0ZLbldHSk1USmZBMDMwb1YyQ2ZSRGdTV09pd3NrVXA3a2liczBFbk5FNTdJMmFab0ZBUmdwQ05oOXVSWGtvbU5EaU5ySm55NUpIZmxrMW1VS3ZSUnZ2NzkxT25nanFUaXRIbWxZN2Jmc1Mwb21GRTluVDdRZnEtQXNFelRQMnU4VHRJcVkzcnVkQXBOSjNCVXJpY0tzSkpfVWVFSk1Sc0l6OVd5NWc?oc=5","date":"2021-06-23","type":"pipeline","source":"Pharmaceutical Technology","summary":"Centessa Pharmaceuticals: forging a new path for pharma R&D - Pharmaceutical Technology","headline":"Centessa Pharmaceuticals: forging a new path for pharma R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNQjBXeUNHdElldjJRZ0gtVUxTNFdaNWtjTnpCbFBhU2NJMVMyNWlSS2U0YTRfcnR0bTRoNVhfZHBMZC1zOUJIUHA4UlpaZVQ0TzUyajA1d0EwYnNpMmlsdE8tMkpaUEFfd2JlUzVqMlhCWkVMZng0amlCWVNPWGJ0bDFzUTZ0MF9mNXJCdU90cWZ0ODYtcF9EZC1pQ0tZbFl3WmRBNFpua3RSeFRtX3NsYVlxZU1VTFVUUVdxbUNiVU9KYlhaU19vR0RvSVBfMDhYbUZlMlJla1A0cndSbExHMzUtYWtPYTNLUzZLckhteUV0VU1sREhNYkZyeHd1YWExVGVfRHRLZXBsYjA?oc=5","date":"2021-02-16","type":"pipeline","source":"Business Wire","summary":"Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model - Business Wire","headline":"Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Mode","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOQzdsWFNNdlV5dnVJX0hwaDRDVWRfX0oyY0dNazlJYlhCSDJLRFo3Q0JydFhDalpzRzRjZlRtS2ltQmhnX05ELTJ3bEthYnZZV09LVDM2TXlwNDIyMW5SRElnbFJ2MjNNbnR3WFhmTTFJcDJMbHJGVGJOVlNaWDJDUXdkaWRSaXA4aDRHRTdtRC0yUlh1YV94WHhCb2dxQ0xRQ3RNTmdTWlQ2cWRiakV5TlZ5TUNOS3pVeWYxa1d2dUN2alk4WjFBUnJTc0VTLWdwcmV3NmI4MkZTWmxoWmFQMGpJLTF4ZlFQcmljS3B1WldBaWNSVjNsSG5jZ05ya3ZaeThfalRNMzJaYmM?oc=5","date":"2021-02-16","type":"trial","source":"Endpoints News","summary":"Francesco De Rubertis makes his legacy play, recruiting star execs and rolling up 10 biotech startups into a $250M gamble on creating something new in pharma - Endpoints News","headline":"Francesco De Rubertis makes his legacy play, recruiting star execs and rolling up 10 biotech startups into a $250M gambl","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNV2FvUUItMEMxbnB6OEl6ZFc0US1iaUx0NUJ5SUlfa3BiWkdkQVpMTFR4QWJUZWFsWFdLU0JGcHdGTDN0TEpJelhLcWY5b2F5SjJ5MEUxNkxOYld4M0RLRTRmSGRicDNyQThmc1FHZFlKRWJKam9QLXBNOGczM2x0ZGtvTWdBOFE5c2N6ZmlHaXdPQk82TXJtMUVnMzBBanZzNmlpekw0M3R3aXVKaXpuMEpsYl9ERjlUWDg3M3RjMjdVbVdjV3NiTVZLTkFNQ0ZiVEtRVXpqU3hqRUdZRUZHVlJJeS1zOGFVeHlkcGJxLWp0ZDRodXljSDVZa3pJT3ZIN2ZWTDJtdWxpcDBRdnFiZWFjOVdFRjJt?oc=5","date":"2021-02-15","type":"deal","source":"marketscreener.com","summary":"Centessa Pharmaceuticals Limited acquired Palladio Biosciences, Inc. from Medicxi Ventures (UK) LLP and others. - marketscreener.com","headline":"Centessa Pharmaceuticals Limited acquired Palladio Biosciences, Inc. from Medicxi Ventures (UK) LLP and others.","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}